Marketed TZM is a sterile, pale yellow, lyophilized, preservative-free powder, reconstituted in bacteriostatic water solution prior to intravenous administration, authorized by the EMA and FDA regulatory bodies for the management and/or treatment of HER2 neu-positive breast (BC) and gastric (GC) cancer [11]. This evidence concerns the gene ERBB2 and gastric cancer.